Pharmaceutical company profits are back. The anything-goes days of pharmaceutical industry funding are gone. But if industry reps say budgets for funding meetings are shrinking, it sure isn't because of profitability. Take a gander at these third- quarter income numbers: Merck & Co. up 16 percent; Johnson & Johnson up 20 percent on a 14 percent sales increase; and Schering-Plough Corporation up 15 percent. The amazing part, according to a recent report in the Wall Street Journal, is ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to Corporate Notes, you'll get exclusive access to a large archive of premium content.

Already registered? here.